Intellia Therapeutics to present data from the Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting

Intellia Therapeutics announced that data from the Phase 2 study of NTLA-2002 will be presented at the 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, taking place 24-28 October 2024 in Boston, Massachusetts.

Presentation Details:

Title: Results From a Phase 2, Randomized, Placebo-Controlled Trial of CRISPR-Based Therapy NTLA-2002 for Hereditary Angioedema

Session: Distinguished Industry & Late-breaking Oral Abstracts – Session 1

Date and Time: Saturday 26 October 2024 from 4:30 – 6:30pm Eastern Time

Presenter: Danny Cohn MD PhD, Internist, Department of Vascular Medicine, Amsterdam University Medical Center

(Source: Intellia)